WeedMD Inc. is a producer licensed by Health Canada under the Cannabis Act. WeedMD has a team of knowledgeable professionals that can provide physicians and clients the resources and guidance needed to customize the best treatment plans. The products are laboratory tested by a third-party to ensure clients have access to safe and consistent products.
WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc. The company owns and operates a facility located in Strathroy, Ontario. The 158 acre state-of-the-art greenhouse, outdoor and processing facility is productive. The headquarters of the company are in Ontario. The company was founded in 2014.
WeedMD Inc. is (TSX-V:WMD) and (OTCQX:WDDMF) and (FSE:4WE). The company has a wholly-owned subsidiary called CX Industries Inc. or CX. This subsidiary specializes in extraction, toll processing and third-party product formulation from WeedMD's fully-licensed Aylmer, Ontario facility. CX Industries Inc. will have the ability to process more than 200,000 kg of biomass at its peak level production in 2020. WeedMD Inc. company owns the 26,000 sq. ft. extraction and processing facility in Aylmer, Ontario operating as CX Industries Inc.
WeedMD has an effective distribution strategy. The strategy includes selling directly to medical patients, relationships across the seniors' market and supply agreements with Shoppers Drug Mart. Also, there are agreements with 6 provincial distribution agencies where WeedMD's adult-use brand Color Cannabis is sold.
Investors are interested in the WeedMD Inc. stock. It is worth about 30% less than CannTrust (TSX:TRST). WeedMD (TSXV:WMD) is cheaper than a lot of other cannabis stocks.
Recently, WeedMD announced that it is buying up Starseed, a union-backed medical cannabis company. The acquisition of Starseed has many advantages. It improves the customer reach.
As WeedMD goes forward, the company is making an effort to continue to lower its growing costs while maintaining its high-quality product. In the most recent quarter, its average costs were down another 22% to $1.42/gram for all-in sales costs.
The upcoming marijuana boom could benefit this company. Investors should consider the advantages of these types of markets.